Trials / Withdrawn
WithdrawnNCT04889495
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.
Conditions
- Non-small Cell Lung Cancer
- Metastatic Colorectal Cancer
- Metastatic Breast Cancer
- Metastatic Kidney Cancer
- Cervical Cancer
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zirabev | Bevacizumab biosimilar |
Timeline
- Start date
- 2025-05-16
- Primary completion
- 2025-08-16
- Completion
- 2025-08-16
- First posted
- 2021-05-17
- Last updated
- 2025-03-19
Source: ClinicalTrials.gov record NCT04889495. Inclusion in this directory is not an endorsement.